The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina
Résumé
Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). VEGF is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction.
Origine : Fichiers produits par l'(les) auteur(s)
Loading...